Erris Resources (ERIS) Armadale Capital (ACP) Vadim Alexandre on Evgen (EVG)
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast:
Erris Resources (ERIS)
Merlin Marr-Johnson, Chief Executive Officer of Erris Resources #ERIS discusses the High grade Zinc-Lead-Silver Grades returned at Abbeytown Project in Ireland.
Erris Resources plc (EPIC: ERIS.L) is an AIM quoted, European focused, discovery driven exploration company. Supported by Canadian mining majors, Osisko Gold Royalties, which has a 18.9% interest in the Company, and Centerra Gold KB Inc, a wholly owned subsidiary of TSX listed Centerra Gold Inc., the Company has an established portfolio of zinc assets in Ireland and gold projects in Sweden, which it is looking to further build on. Led by a highly qualified team with extensive corporate and sector experience, Erris Resources' strategy is to create shareholder value through commercial discovery of base or precious metal assets in proven mineral districts and in favourable European jurisdictions.
(Interview starts at 1 minute 38 seconds)
Armadale Capital (ACP)
Matt Bull, Exploration Manager at Armadale Capital (ACP) discusses the progress they're making at their Graphite project in Tanzania ahead of an anticipated decision to mine in early 2019.
Armadale Capital Plc is focused on investing in and developing a portfolio of investments, targeting the natural resources and/or infrastructure sectors in Africa. The Company, led by a team with operational experience and a strong track record in Africa, has a strategy of identifying high growth businesses where it can take an active role in their advancement. The Company owns the Mahenge Liandu graphite project in south-east Tanzania, which is now its main focus. The Project is located in a highly prospective region with a high-grade JORC compliant inferred mineral resource estimate of 51.1Mt @ 9.3% TGC.
(Interview starts at 11 minutes 25 seconds)
Vadim Alexandre on Evgen (EVG)
Vadim Alexandre, Managing Director of Northland Capital Partners discusses Evgen (EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions.
Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
(Interview starts at 17 minutes)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.